Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.
Avalyn Pharma advances inhaled AP02 into Phase 2 trials for IPF. Learn how lung targeted delivery could reshape antifibrotic treatment.
Baseimmune launches IPF pipeline using computational multi-pathway antigen design. Preclinical readouts due 2026-27. Discover what this means for fibrosis drug development.
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
Trevi’s IPF cough trial results for nalbuphine ER get published in JAMA. Find out what this means for future approvals and respiratory drug development.
Cereno Scientific has announced the peer-reviewed publication of its next-generation HDAC inhibitor CS014 in the Journal of Thrombosis and Haemostasis, revealing the compound’s ability to significantly reduce thrombosis without increasing bleeding risk. The study marks the first formal disclosure of CS014’s chemical structure and nonclinical pharmacology, positioning the compound as a differentiated HDAC inhibitor with […]
Boehringer Ingelheim has secured approval from the United States Food and Drug Administration for Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. The decision follows earlier FDA clearance for Jascayd in idiopathic pulmonary fibrosis and now marks the first time a preferential PDE4B inhibitor with dual immunomodulatory and antifibrotic effects has […]